Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.45 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259502 | 0.94 | FBP1 (0.53) | FBP1P2RY6P2RY2P2RY4 | |
| SCHEMBL26074117 | 0.94 | FBP1 (0.53) | FBP1P2RY6P2RY2P2RY4 | |
| SCHEMBL14985142 | 0.94 | FBP1 (0.53) | FBP1P2RY6P2RY2P2RY4 | |
| SCHEMBL14985143 | 0.93 | FBP1 (0.56) | FBP1P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL23657026 | 0.93 | FBP1 (0.56) | FBP1P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL14619450 | 0.92 | P2RY2 (0.53) | FBP1P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL10014684 | 0.92 | FBP1 (0.50) | FBP1P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL19760432 | 0.88 | FBP1 (0.53) | FBP1P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL13002355 | 0.87 | FBP1 (0.43) | FBP1P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL13002370 | 0.87 | FBP1 (0.43) | FBP1P2RY14P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172959-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20230096443-A1 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | NUVAMID SA (CH) | 2023-03-30 | — | — | US | disclosed |
| US-20230002368-A1 | USE OF COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF ANKYLOSING SPONDYLITIS, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172959-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS | NNT, NAMPT, UTRN | FBP1 334/4885P2RY14 302/4885P2RY6 204/4885 |
| US-20230002368-A1 | USE OF COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF ANKYLOSING SPONDYLITIS, AND CORRESPONDING COMPOSITIONS | SOST, TNF, NFKBIA | FBP1 1555/4885P2RY14 3930/4885P2RY6 2684/4885 |
| US-20230096443-A1 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | NNT, NAMPT, NQO1 | FBP1 1241/4885P2RY14 215/4885P2RY6 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.